癌基因
小RNA
长非编码RNA
癌症研究
生物
转移
肝细胞癌
细胞生长
小核仁RNA
癌症
核糖核酸
基因
非编码RNA
细胞周期
遗传学
作者
Daiwei Wan,Shunli Shen,Shunjun Fu,Burnley Preston,Coder Brandon,Songbing He,Cunsi Shen,Jian Wu,Sutong Wang,Wenlin Xie,Bin Chen,A Li-ya,Yixing Guo,Dingcheng Zheng,Qiaoming Zhi,Baogang Peng
出处
期刊:Anti-cancer Agents in Medicinal Chemistry
[Bentham Science]
日期:2016-02-18
卷期号:16 (4): 414-423
被引量:45
标识
DOI:10.2174/1871520615666150716105955
摘要
MicroRNAs (miRNAs) have been integrated into tumorigenic programs by regulating genes at post-transcriptional level. Long non-coding RNAs (lncRNAs) are novel targets for miRNAs. Here, we reported that miR-203 down-regulation was closely linked to advanced clinical features and poor overall survival (OS) of patients with hepatocellular carcinoma. We also confirmed that miR-203 and oncogene ADAM9 (a disintegrin and metalloproteinase 9)/oncogenic long non-coding RNA HULC (highly up-regulated in liver cancer) were inversely expressed in hepatocellular carcinoma (HCC) tissues or cell lines. More intriguingly, up-regulation of miR-203 diminished the expression of ADAM9 and HULC in HCC cancer cells. Over-expression of miR-203 could markedly inhibit cell proliferation, invasion and induce cell apoptosis. Furthermore, we identified that miR-203 modulated ADAM9 and HULC in a novel post-transcriptional regulatory mechanism. Over-expression of HULC partly rescued the miR-203-mediated antitumor effects. These results suggested that miR-203 played tumor suppressive roles by downregulating ADAM9 and HULC and indicated its potential application in cancer treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI